December 20, 2011
MabCure (MBCI): A Revolutionary Improvement to a Proven Cancer Technology
MabCure Inc. (PINK SHEETS: MBCI) is a biotechnology company focused on changing the perception that cancer is an incurable disease. Unlike Dendreon Corporation (NASDAQ: DNDN) or Generex Biotechnology Corporation (PINK SHEETS: GNBT), the company is developing monoclonal antibodies against tumor-specific antigens for diagnosis and treatment using its proprietary technology.
Improving Upon a Classic Solution
Hybridoma technology is used to form hybrid cell lines by fusing a specific antibody-producing B cell with a myeloma cell that is selected for its ability to grow in a tissue culture. . While this technology has been used to produce highly specific monoclonal antibodies (Mabs), it is far less efficient than recombinant DNA technology such as Phage Display, which can generate copious amount of Mabs in a short time. However, Phage Display technology requires the knowledge and availability of the desired target antigen, which is not the case with Hybridoma technology.
When one is searching for unknown antigens such as tumor specific markers, the use of hybridoma technology is the preferred mode. Yet, because of the inherent production limitations of the hybridoma technology, MabCure has re-engineered this classic technology into a highly efficient and optimized one. In particular, the company’s approach overcomes several key problems:
- Large quantities of antibodies can be produced in a relatively short time against putative tumor markers. This a huge improvement over the traditional hybridoma technology.
- Antigens are preserved in their natural conformations, which means that the cell lines can better recognize and bind more selectively to tumor cells.
From Diagnostics to Therapeutics
MabCure has developed a highly effective business model that starts with cancer diagnostics and ends with therapeutics. After all, cancer diagnostics have lower development costs, faster time-to-market and offer a great jump-off point to the cancer therapeutics market. The result is nearer-term revenues and less dilution for the company’s shareholders.
Cancer diagnostics is also extremely important for another reason. The public fails to appreciate the fact that early detection of cancer (Stage 1)can result in a 5-year survival rate greater than 90%, according to the National Cancer Institute. If cancer isn’t detected early, the Stage 3 and 4 survival rates drop dramatically to a range of 9%-30%.
A Great Investment Opportunity
MabCure offers investors a unique opportunity to capitalize on a revolutionary new way to detect and treat cancer. By improving upon a proven lab technology, the company is bringing an exciting and efficacious new solution to market. With a prudent business model that has shareholders in mind, there is significant near-term potential.
To learn more about MabCure, please see the following resources:
Comments are closed.